2.7.5 参考文献

1) 【5.4-20】Malik M. Facts, fancies and follies of drug-induced QT/QTc interval shortening. Br J Pharmacol. 2010 Jan; 159(1): 70-6.
2) 【5.4-21】Shah RR. Drug-induced QT interval shortening: potential harbinger of proarrhythmia and regulatory perspectives. Br J Pharmacol. 2010 Jan; 159(1): 58-69.
3) 【5.4-24】Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005 Mar; 365(9463): 947-54.
4) 【5.4-05】Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988 Jun; 51(6): 745-52.
5) 【5.4-06】柳澤 信夫．厚生省特定疾患・神経変性疾患調査研究班：厚生省特定疾患神経変性疾患調査研究班パーキンソン病診断基準．1995 年度研究報告書 1996, p22-7.
6) 【5.4-07】Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015 Oct; 30(12): 1591-601.
7) 【5.4-11】「パーキンソン病診療ガイドライン」作成委員会編集．日本神経学会監修．パーキンソン病診療ガイドライン 2018．医学書院．2018.
8) 【5.4-25】National Institute for Health and Care Excellence. Parkinson's disease in adults. NICE guideline 2017, Published: 19 July 2017. https://www.nice.org.uk/guidance/ng71